All In MedTech

FDA Clearance Tracker · P250010

Proliv™Rx System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (this decision)Source: openFDAMethods & limitations

PMABreakthrough

Decided

Dec 31, 2025

Approved

Time to decision

280 days

Received Mar 26, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P250010
Device name
Proliv™Rx System
Applicant location
Netanya
Received
Mar 26, 2025
Decided
Dec 31, 2025
Decision
Approved

Device type

Device class
Class III
Regulation
21 CFR 882.5800

Every decision under product code JXK

FDA's approval statement

As written in FDA's record.

The Proliv™Rx System provides focal external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) treatment. It is intended as an adjunctive treatment for Major Depressive Disorder (MDD) in adults who failed to achieve satisfactory improvement from at least one previous antidepressant medication, for use at home or in clinic. It is a prescription-only device.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code JXK. The earliest in FDA's data is P230024, decided Dec 8, 2025.
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for Neurolief , Ltd.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.